))
Novel developments in lower-risk MDS & important practical considerations when treating patients
Manage episode 428981092 series 2838329
Indhold leveret af VJHemOnc. Alt podcastindhold inklusive episoder, grafik og podcastbeskrivelser uploades og leveres direkte af VJHemOnc eller deres podcastplatformspartner. Hvis du mener, at nogen bruger dit ophavsretligt beskyttede værk uden din tilladelse, kan du følge processen beskrevet her https://da.player.fm/legal.
In today’s VJHemOnc podcast, we will be sharing novel developments in lower-risk myelodysplastic syndromes (LR-MDS) and important practical considerations when treating patients.
You will hear from experts Amer Zeidan, MBBS, Yale University and Yale Cancer Center, New Haven, CT, Rena Buckstein, MD, FRCPC, Odette Cancer Research Program, Sunnybrook Research Institute, Toronto, Canada, Guillermo Garcia-Manero, MD, University of Texas MD Anderson Cancer Center, Houston, TX, and Andrew Brunner, MD, Massachusetts General Hospital, Boston, MA. They discuss important considerations for physicians when treating LR-MDS, providing valuable insights into some of the common pitfalls in clinical practice which may lead to suboptimal responses in patients.
200 episoder
Del
